Welcome to our dedicated page for Pharvaris news (Ticker: PHVS), a resource for investors and traders seeking the latest updates and insights on Pharvaris stock.
Pharvaris N.V. reports developments as a late-stage biopharmaceutical company developing oral bradykinin B2 receptor antagonists for bradykinin-mediated diseases, including hereditary angioedema and acquired angioedema due to C1 inhibitor deficiency. Its lead program, deucrictibant, is being developed in immediate-release capsule and extended-release tablet forms for on-demand and prophylactic treatment settings.
Recurring updates include clinical data from the RAPIDe and CHAPTER study programs, patient-reported outcome research, scientific publications, presentations at allergy and immunology meetings, financial results, strategic priorities, shareholder voting matters and capital-structure disclosures.
Pharvaris (Nasdaq: PHVS) reported second quarter 2026 results and a business update focused on its oral bradykinin B2 receptor antagonist deucrictibant for hereditary and acquired angioedema. Cash and cash equivalents were €318 million as of June 30, 2026, versus €292 million at year-end 2025, supported by a $132.3 million underwritten share offering that, according to the company, extends its cash runway into 2028. Q2 2026 loss was €47.8 million, with R&D expenses of €35.0 million and G&A expenses of €15.8 million.
Topline data from CHAPTER-3, a pivotal Phase 3 prophylaxis trial of deucrictibant XR in HAE, are expected in 3Q2026, with enrollment in CHAPTER-4 and the AAE-C1INH Phase 3 CREAATE study progressing. The FDA is reviewing the deucrictibant IR NDA (PDUFA April 23, 2027), and the EMA has validated the MAA. Pharvaris also opened a U.S. expanded access program for deucrictibant IR and promoted Peng Lu to President to align research, development, and commercial functions.
Pharvaris (Nasdaq: PHVS) reported publication in Frontiers in Immunology of the first in-depth qualitative study of acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), an ultra-rare, serious disease with no approved therapies for prevention or treatment of bradykinin-mediated angioedema attacks.
The interviews characterized frequent, painful swelling attacks, prolonged misdiagnoses, emergency care, and broad physical, emotional, social, and work-related impact, with participants relying on off-label therapies. The study evaluated established patient-reported outcome tools (PGI-C, PGI-S, PGA) and found them relevant and interpretable in AAE-C1INH, showing a PGI-C rating of “better” as consistently meaningful up to 4 hours post treatment. According to Pharvaris, these findings informed endpoint selection and design of the ongoing Phase 3 CREAATE trial (NCT07266805) of deucrictibant for prophylaxis and on-demand treatment of AAE-C1INH attacks.
Pharvaris (Nasdaq: PHVS) announced the publication of a comprehensive review in Clinical Reviews in Allergy & Immunology summarizing decades of scientific and clinical evidence on bradykinin biology and the bradykinin B2 receptor (B2R). The article outlines the evolution of B2R antagonism from basic kinin research to a clinically validated therapeutic approach for bradykinin-mediated angioedema, including hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH). According to Pharvaris, the review highlights that B2R antagonists directly block the receptor through which bradykinin drives swelling, independent of upstream mechanisms, and notes that long-term unfavorable effects from B2R antagonism have not been observed to date. The publication also discusses potential applicability of B2R-targeted therapies across broader immunological and inflammatory diseases.
Pharvaris (Nasdaq: PHVS) announced FDA acceptance of its New Drug Application for deucrictibant IR 20 mg capsules as an on-demand treatment for hereditary angioedema (HAE) attacks, with a PDUFA action date of April 23, 2027.
The NDA includes data from over 1,300 HAE attacks. In the pivotal Phase 3 RAPIDe-3 trial, deucrictibant IR met the primary and all 11 secondary efficacy endpoints with statistical significance, showing rapid symptom relief and a well-tolerated safety profile. Deucrictibant received FDA orphan drug designation in 2022.
Pharvaris (Nasdaq: PHVS) reported new EAACI 2026 data on oral deucrictibant for hereditary angioedema (HAE). Phase 3 RAPIDe-3 showed median 1.28 hours to symptom relief and 11.95 hours to complete resolution versus over 12 and 48 hours with placebo, and a median 17.47 minutes to End of Progression™ versus 228.67 minutes.
In Phase 2 CHAPTER-1 long-term prophylaxis, attack rates fell by ~92% on average and about half of participants were attack-free. An integrated analysis in ~570 participants showed a favorable cardiovascular safety profile, and a validated kinin biomarker assay may help differentiate bradykinin-mediated angioedema.
Pharvaris (Nasdaq: PHVS) announced its annual general meeting of shareholders will be held on Friday, June 26, 2026, at 16:00 CEST (10:00 a.m. EDT).
Meeting documents, including the notice and agenda, are available in the website’s Investors > Events & Presentations section and on the SEC website.
Pharvaris (Nasdaq: PHVS) will present new clinical data on its oral bradykinin B2 receptor antagonist deucrictibant at the EAACI Annual Congress 2026 in Istanbul from June 12-15, 2026.
According to Pharvaris, one oral presentation and seven flash talk/poster sessions will cover Phase 3 RAPIDe-3 and Phase 2 CHAPTER-1 results in hereditary angioedema, cardiovascular safety, biomarker development, long-term prophylaxis, and patient-reported outcomes. Slides and posters will be posted on its investor website at the time of each presentation.
Pharvaris (Nasdaq: PHVS) reported first quarter 2026 results and a late-stage HAE pipeline update. Cash and cash equivalents were €247 million on March 31, 2026, excluding a subsequent $132.3 million underwritten offering that is expected to extend the cash runway into 2028.
Topline data from Phase 3 CHAPTER-3 of deucrictibant XR for prophylactic HAE treatment are expected in 3Q2026, and an NDA for deucrictibant IR for on-demand HAE treatment remains on track for 1H2026. Enrollment continues in the CHAPTER-4 extension and CREAATE Phase 3 AAE-C1INH study.
Pharvaris (Nasdaq: PHVS) closed an underwritten public offering of 4,455,863 ordinary shares, including full exercise of the underwriters’ option for 581,199 additional shares. Gross proceeds were approximately $132.3 million before fees and expenses. All shares were sold by Pharvaris under an effective SEC shelf registration.
Pharvaris (NASDAQ: PHVS) priced an underwritten offering of 3,874,664 ordinary shares at $29.68 per share, with gross proceeds expected to be approximately $115 million before underwriting discounts, commissions and expenses.
The underwriters have a 30-day option for an additional 581,199 shares. The offering is expected to close on or about May 11, 2026, subject to customary closing conditions.